Biocon Limited — PPTs, 08-08-2025: Investor Presentation

Here's the summary:

**Financial Highlights:**

Q1 FY26 saw Total Revenue climb 15% YoY to ₹3,942 Cr. Core EBITDA grew 11% YoY to ₹1,003 Cr, maintaining a 25% margin. A strategic ₹4,500 Cr QIP bolstered the balance sheet, set to increase Biocon Biologics stake and enhance financial flexibility.

**Strategic Initiatives & Growth Drivers:**

Key approvals include US FDA nod for Kirsty (bInsulin Aspart), the first interchangeable rapid-acting insulin in the US. Yesafili (biosimilar Aflibercept) launched in Canada, and bDenosumab received approvals, marking entry into bone health. New GLP-1 injectable and expanded Cranbury facilities are enhancing US market access. Syngene also opened a new peptide lab.

**Business Developments:**

Acquired Cranbury and Bayview facilities are crucial for supply chain resilience. A Civica alliance aims for local US insulin manufacturing. Biocon Biologics focuses on scaling commercial products, while CRDMO’s Bengaluru facility is operational, with Bayview (US) commissioning soon.

**Market Position & Competitive Advantage:**

Yesintek is an early leader in North American immunology, and Hulio maintains a leading position in Germany. The oncology portfolio shows strong momentum. Generics' early investments in GLP-1s and peptide APIs are gaining traction, indicating future growth.

**Investor Implications:**

Q1 FY26 marks a strong start with accelerated growth across all segments. Strategic launches and capacity expansions position Biosimilars and CRDMO for continued success. Generics' pipeline promises double-digit growth. These updates suggest positive growth potential and a strengthened financial outlook.